Clinical Trial Update: Tezosentan in Patients With Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 trial of tezosentan for pulmonary arterial hypertension was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Tezosentan (tezosentan)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED